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Abstract
Background: Drug susceptibility testing (DST) patterns of Mycobacterium tuberculosis (MTB) from patients with
rifampicin-resistant tuberculosis (RR-TB) or multidrug-resistant TB (MDR-TB; or resistant to rifampicin and isoniazid
(INH)), are important to guide preventive therapy for their household contacts (HHCs).
Methods: As part of a feasibility study done in preparation for an MDR-TB preventive therapy trial in HHCs, smear,
Xpert MTB/RIF, Hain MTBDRplus, culture and DST results of index MDR-TB patients were obtained from routine TB
programs. A sputum sample was collected at study entry and evaluated by the same tests. Not all tests were
performed on all specimens due to variations in test availability.
Results: Three hundred eight adults with reported RR/MDR-TB were enrolled from 16 participating sites in 8
countries. Their median age was 36 years, and 36% were HIV-infected. Routine testing on all 308 were confirmed as
having RR-TB, but only 75% were documented as having MDR-TB. The majority of those not classified as having
MDR-TB were because only rifampicin resistance was tested. At study entry (median 59 days after MDR-TB
treatment initiation), 280 participants (91%) were able to produce sputum for the study, of whom 147 (53%) still
had detectable MTB. All but 2 of these 147 had rifampicin DST done, with resistance detected in 89%. Almost half
(47%) of the 147 specimens had INH DST done, with 83% resistance. Therefore, 20% of the 280 study specimens
had MDR-TB confirmed. Overall, DST for second-line drugs were available in only 35% of the 308 routine specimens
and 15% of 280 study specimens.
Conclusions: RR-TB was detected in all routine specimens but only 75% had documented MDR-TB, illustrating the
need for expanded DST beyond Xpert MTB/RIF to target preventive therapy for HHC.
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Background
In 2018, globally an estimated 484,000 people devel-
oped TB with strains resistant to rifampicin (RIF),
and of these, 78% had resistance to both RIF and iso-
niazid (INH), or multidrug-resistant TB (MDR-TB)
[1]. In recent years, rapid and sensitive tests based on
molecular methods, including Xpert MTB/RIF (Xpert,
Cepheid, Sunnyvale USA) and line probe assays (LPA)
such as the Hain GenoType MTBDRplus assay (Hain,
Hain Lifescience, Nehren, Germany), have been en-
dorsed by the World Health Organization (WHO)
and have become routinely available in TB programs
in several countries. Diagnostic algorithms for MDR-
TB vary across countries [2].
The optimal preventive therapy regimen for people
exposed to MDR-TB is not known and evidence
based guidelines are urgently needed. Current WHO
guidelines recommend that the preventive treatment
should be individualized after a careful assessment of
the intensity of exposure, the certainty of the source
case, reliable information on the drug resistance pat-
tern of the source case and potential adverse events.
They also acknowledge the lack of quality evidence
and specifically recommend clinical trials as a high
priority. Three large phase 3 trials are underway to
address this question. Two are evaluating levofloxa-
cin versus placebo: TB-CHAMP (ISRCTN92634082)
and VQUIN MDR (ACTRN12616000215426), and
the PHOENIx trial comparing the efficacy and safety
of delamanid versus isoniazid (NCT03568383). We
conducted a feasibility study in preparation for the
PHOENIx trial The feasibility study evaluated index
cases with reported MDR-TB and their HHCs at 16
sites, in eight high TB burden countries [3]. The ob-
jectives of the feasibility study were to (1) identify,
recruit, and characterize adult MDR-TB index cases
and their adult and child HHCs; (2) describe the
prevalence of TB disease, TBI, and HIV among
HHC; and (3) estimate the proportion of HHCs at
high risk of TB and, therefore, potentially eligible for
the interventional trial. Briefly, we found that partici-
pating sites were readily able to find and recruit pa-
tients with MDR-TB and their HHC. Many of the
latter had either prevalent TB infection or disease,
or were otherwise at high risk for TB, and very few
were receiving preventive therapy. The mycobacter-
iology objectives for this publication were to deter-
mine if MTB was detectable and if resistance to INH
and RIF could be confirmed, genotypically and
phenotypically, in the adult index cases with drug re-
sistant TB at time of enrolment. Here we report the
mycobacteriology results and discuss how they in-




In this cross-sectional study, index cases were adults 18
years or older with pulmonary MDR-TB or rifampicin-
resistant-TB (RR-TB) by phenotypic or genotypic
testing. Index cases identified by the site or local TB
program with pulmonary MDR/RR-TB were all
approached for enrollment if they met the following
additional inclusion criteria: (1) initiated MDR-TB treat-
ment within 6 months prior to study enrollment, (3) had
at least one household contact (HHC), (4) provided per-
mission to enumerate and screen HHCs, and (5) resided
at a distance deemed by the site study team close
enough for study conduct. The study enrolment period
was October 2015 to April 2016. TB treatment was pro-
vided by the routine TB programs according to local
guidelines. The study was approved by site Institutional
Review Boards or Ethics Committees and all participants
gave written informed consent.
Study procedures
The mycobacteriology results from sputum specimens
from the routine program (hereafter referred to as rou-
tine specimens) for MDR/RR-TB diagnosis were re-
corded; these included smear microscopy, Xpert, LPAs,
culture and DST. Not all tests were performed across
sites due to variations in test availability. A sputum sam-
ple was collected at study entry (hereafter referred to as
study specimens). Smear microscopy (GLI-WHO-
IUATLD grading scale [4]), Xpert, and liquid culture
using MGIT (Mycobacteria Growth Indicator Tube, BD
Diagnostics, Sparks, MD) were performed. Solid culture
was optional. Positive cultures were identified using an
MPT64 antigen assay and/or Hain MTBDRplus, as the
latter was not available in all participating laboratories.
When done, phenotypic DST for first and second line
TB drugs was performed by either MGIT or another in-
direct proportion method using WHO critical concen-
trations [5] at some sites.
Definitions
Time since RR/MDR-TB diagnosis for microbiology
testing was defined as the interval between the date of
treatment initiation and the date the study specimen was
obtained. Pre-extensively drug-resistant TB (Pre-XDR-
TB) was defined as MDR-TB with resistance to fluoro-
quinolones (FLQ) or second-line injectable drugs (SLID).
XDR-TB was defined as MDR-TB plus resistance to any
fluoroquinolones and any of the SLID [1]. When mul-
tiple specimens were available, results were classified
based on the “worst” result; for example, if one smear
was positive and the others negative, the overall smear
result was classified as positive. For culture, determinate
results were prioritized over those contaminated. For
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both routine and study specimens, if DST results were
obtained by several methods, the overall result was clas-
sified as resistant if reported as such by at least one
method. Results were described as discordant when DST
results for one drug were different when tested by
various methods (between molecular assays and/or
phenotypically).
Statistical considerations
All summaries are descriptive. We calculated simple
proportions for categorical variables and medians (inter-
quartile ranges (IQR)) for quantitative variables.
Results
Study participants
Three hundred twenty-eight potential participants were
approached of whom 321 agreed to be screened. Three
hundred eight were enrolled between October 2015 and
March 2016 from 16 participating sites in 8 countries:
Botswana, Brazil, Haiti, India, Kenya, Peru, South Africa,
and Thailand. All sites are clinical research sites of the
AIDS Clinical Trials Group (ACTG) and/or the Inter-
national Maternal Pediatric Adolescent AIDS Clinical
Trials (IMPAACT) networks. The median age was 36
years and 57% were male; 41% of participants were
black, 32% mixed race/other, 22% Asian, and 2% white;
112 (36%) were HIV-infected; and 43% were current or
former smokers. 87 (43%) had documented cavitary pul-
monary disease and 161 (52%) had received prior TB
treatment.
Quantity and timing of specimen collection
The 308 participants had one to 4 sputum sample results
from the routine program available which had estab-
lished the MDR-TB diagnosis, for a total of 404 speci-
mens recorded. Of the 308 participants, 27 (9%) could
not produce sputum, 1 declined to provide a study sam-
ple, and the remaining 280 (91%) had a study sputum
specimen collected at a median (range) of 59 days (0,
190) after MDR-TB treatment initiation.
Smear and MTB detection by Xpert, Hain and culture
For routine specimens, 217/308 (71%) of participants
had smear results available: 69% (149/217) were positive.
All study specimens underwent smear testing; only 34%
(94/280) were acid-fast bacilli positive, with lower smear
grading values (Table 1). Xpert results of routine speci-
mens were available for 152/308 (49%) participants and
all but 2 reported MTB. Almost all study specimens
were tested by Xpert (99%; 278/280) but detected MTB
in only 51% (141/278). Hain testing of routine specimens
or positive cultures was reported in 69% (214/308), with
MTB detected in 99%. Hain testing was performed on
only 27 study specimens or positive cultures (10%; 27/
280) and detected MTB in 21 (78%; 21/27). Liquid and/
or solid culture results were available for 63% (193/308)
routine and 98% (274/280) study specimens while re-
ported positive for MTB in 93% (179/193) and 31% (85/
275), respectively. Overall, MTB was detected by Xpert,
Hain and/or culture in all participants from routine
specimens, and in 53% (147/280) of study specimens
collected on treatment.
Rifampicin susceptibility testing
RIF DST results for routine and study specimens are
shown by testing method in Table 2, and combining
Xpert, Hain and phenotypic results in Table 3 and Fig. 1.
In the routine specimens positive for MTB, RIF resist-
ance was detected in 99, 99 and 100% when tested by
Xpert, Hain and phenotypic DST, respectively. If RIF re-
sistance was not detected by one method, it was demon-
strated by another. Overall for all combined methods,
there was evidence of RIF resistance in all 308 routine
specimens. For study specimens with MTB detected, RIF
resistance was detected in 89, 81 and 89% of those tested
by Xpert, Hain and phenotypic DST, respectively. Sus-
ceptible and/or discordant results were observed for all
3 methods. Fourteen RIF susceptible Xpert results were
recorded: 12 were not tested by any other method while
2 were also susceptible phenotypically. Three study spec-
imens had RIF resistance detected by Xpert but were
RIF susceptible phenotypically (Table 3). Overall, of the
280 study specimens, 147 (53%) had MTB detected, and
of these, 145 had RIF susceptibility testing done by
either methods, of which 128 (89%) had evidence of RIF
resistance. Therefore, 46% of 280 study specimens had
RIF resistance documented.
INH susceptibility testing
For routine specimens with MTB detected, INH resist-
ance was detected in 91, and 99% of those tested by
Hain and phenotypic DST, respectively (Table 2). Sus-
ceptible and discordant results were observed: six partic-
ipants were INH susceptible by Hain testing but
resistant phenotypically (Table 3). Overall, all 308 rou-
tine specimens had MTB detected. Of these, 246 (80%)
had INH susceptibility testing done by either method, of
which 232 (94%) had evidence of INH resistance. There-
fore, 75% of routine specimens had INH resistance doc-
umented (Table 2). For the study specimens with MTB
detected, INH resistance was detected in 67 and 91%
tested by Hain and phenotypic DST, respectively. Sus-
ceptible and/or discordant results were observed such
as 4 INH susceptible by Hain which were however
not tested by phenotypic DST. There were 5 INH
susceptible results phenotypically tested and not by
Hain (Table 3), Overall, for the 280 study specimens,
147 had MTB detected and of these, 69 (25% of 280)
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had INH DST done by either method, of which 57
(83% of 69) had evidence of INH resistance. There-
fore, only 20% of study specimens had INH resistance
documented (Table 2).
Fluoroquinolones (FLQ) and injectable drug susceptibility
testing
Only 108 (35%) of the 308 participants had FLQ suscep-
tibility results available on routine specimens by either
Hain or phenotypic DST since this was not standard in
most countries: 7 (6%) demonstrated resistance. Of 280
study specimens, only 41 (15%) had FLQ susceptibility
results, with 6/41 (15%) demonstrating resistance (data
not shown). Streptomycin resistance was observed in 38
and 72% of the 29 and 54 routine and study specimens,
respectively. For SLIDs, only 107 (35%) of routine speci-
mens had susceptibility testing done and results by
either Hain or phenotypic DST, with resistance detected
in 8 (7%). For study specimens, only 42 (15%) had SLID
susceptibility results, with 5 (12%) resistant.
Table 1 Smear, Xpert MTB/RIF, Hain MTBDRplus and culture results for MDR-TB index cases from routine and study sputum
specimens
Routine sputum used by TB program for MDR-TB
diagnosis (combined specimens per index case)
Study sputum collected on MDR-TB treat-
ment (one specimen per index case)
n % of done % of 308 n % of done % of 280
Smear donea 217 – 70.5 280 – 100.0
Smear positive 149 68.7 48.4 94 33.6 33.6
Smear 3+ 57 26.3 18.5 20 7.1 7.1
Smear 2+ 39 18.0 12.7 18 6.4 6.4
Smear 1+ 41 18.9 13.3 19 6.8 6.8
Smear scanty 12 5.5 3.9 37 13.2 13.2
Smear negative 68 31.3 22.1 186 66.4 66.4
Xpert done 152 – 49.4 278 – 99.3
Xpert MTB+ 150 98.7 48.7 141 50.7 50.4
Xpert MTB not detected 1 0.7 0.3 135 48.6 48.2
Xpert no result 1 0.7 0.3 2 0.7 0.7
Hain MTBDRplus done 214 – 69.5 27 – 9.6
Hain MTBDRplus MTB+ 211 98.6 68.5 21 77.8 7.5
Hain MTBDRplus MTB not detected 2 0.9 0.6 6 22.2 2.1
Hain MTBDRplus indeterminate 1 0.5 0.3
Liquid culture done 159 – 51.6 274 – 97.9
Liquid culture MTB+ 147 92.5 47.7 82 29.9 29.3
Liquid culture NTM+ 3 1.1 1.1
Liquid culture negative 8 5.0 2.6 168 61.3 60.0
Liquid culture contaminated 4 2.5 1.3 21 7.7 7.5
Solid culture done 64 – 20.8 58 – 20.7
Solid culture MTB+ 57 89.1 18.5 14 24.1 5.0
Solid culture negative 5 7.8 1.6 43 74.1 15.4
Solid culture contaminated 2 3.1 0.6 1 1.7 0.4
Liquid or solid culture done 193 – 62.7 275 – 98.2
Liquid or solid culture MTB+ 179 92.7 58.1 85 30.9 30.4
Liquid or solid culture negative 9 4.7 2.9 172 62.5 61.4
Liquid or solid culture contaminated 5 2.6 1.6 18 6.5 6.4
Any Xpert or Hain or culture done 308 – 100.0 280 – 100.0
Any Xpert or Hain or culture MTB+ 308 100.0 100.0 147 52.5 52.5
MTB+ M.tuberculosis complex detected or positive, NTM nontuberculous mycobacteria
aSmear microscopy using GLI-WHO-IUATLD grading scale [4], smear positive includes scanty, 1+, 2+, and 3+
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MDR and XDR status
Detailed results for INH and RIF for routine and
study specimens are shown in Table 3 and Fig. 1.
MDR-TB was confirmed in 75% (232) of 308 routine
specimens. In study specimens, MTB was detected by
Xpert, Hain or culture in 50, 8 and 30%, respectively
(Table 2 and Table 3) and with INH susceptibility
testing being only possible by Hain or phenotypic
DST, only 20% (55/280) had MDR-TB confirmed.
Monoresistance to INH (0% in routine, 0.7% in study
samples) and monoresistance to RIF (0.3% in routine
and 1.4% in study samples) by phenotypic testing was
rarely documented. In 20% of routine and 23% of
study specimens, only RIF resistance was documented
(mainly by Xpert) with no susceptibility results docu-
mented for INH. When adding FLQ and SLID infor-
mation to the MDR status, 43% (131/308) of the
routine specimens and 8.2% (23/280) of the study
specimens had MDR confirmed but no results for
FLQ and SLID (data not shown). Only 35% of routine
Table 2 Rifampicin (RIF), Isoniazid (INH) and second-line drug susceptibility testing methods and results for MDR-TB index cases
from routine and study sputum specimens
MDR-TB Diagnosis by routine program
(combined specimens per index case)
Study sputum collected after start of MDR-TB
treatment (one specimen per index case)
n % of done % of 308 IC n % of done % of 280 IC
MTB detection (from Table 1)
Xpert MTB+ 150 98.7 48.7 141 50.7 50.4
Hain MTBDRplus MTB+ 211 98.6 68.5 21 77.8 7.5
Liquid or solid culture MTB+ 179 92.7 58.1 85 30.9 30.4
Any Xpert or Hain or culture MTB+ 308 100.0 100.0 147 52.5 52.5
RIF susceptibility testing
Done by Xpert Hain and/or pheno 308 100.0 145 51.8
Resistant by Xpert and/or Hain and/or pheno 308 100.0 100.0 128 88.3 45.7
Done by Xpert 150 48.7 141 50.4
Resistant by Xpert 148 98.7 48.1 125 88.7 44.6
Done by Hain 211 68.5 21 7.5
Resistant by Hain 209 99.1 67.9 17 81.0 6.1
Done by pheno 102 33.1 53 18.9
Resistant by pheno 102 100.0 33.1 47 88.7 16.8
Done by pheno only 29 9.4 3 1.1
INH susceptibility testing
Done by Hain and/or pheno 246 79.9 69 24.6
Resistant by Hain and/or pheno 232 94.3 75.3 57 82.6 20.4
Done by Hain 204 66.2 21 7.5
Resistant by Hain 185 90.7 60.1 14 66.7 5.0
Done by pheno 101 32.8 54 19.3
Resistant by pheno 100 99.0 32.5 49 90.7 17.5
Done by pheno only 42 13.6 48 17.1
FLQ susceptibility testing
Done by Hain and/or pheno 108 35.1 41 14.6
Resistant by Hain and/or pheno 7 6.5 2.3 6 14.6
Streptomycin susceptibility testing
Done by pheno 29 9.4 54 19.3
Resistant by pheno 11 37.9 3.6 39 72.2 13.9
SLID susceptibility testing
Done by Hain and/or pheno 107 34.7 42 15
Resistant by Hain and/or pheno 8 7.5 2.6 5 11.9 1.8
FLQ fluoroquinolones (FLQ), MTB+ M.tuberculosis complex detected or positive, pheno phenotypic drug susceptibility testing, SLID second-line injectable drugs
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specimens and 14% study specimens had testing suffi-
cient to determine participants’ pre-XDR and XDR
status. Approximately a third (88/308; 29%) of routine
specimens and 9% (24/280) of study specimens had
MDR with documented susceptibility to FLQ and
SLID. Very few had pre-XDR (7/108 (7%) routine and
5/39 (13%) study) or XDR-TB (4/108 (4%) of routine
and 2/39 (5%) of study) (data not shown).
Table 3 MDR status of Index Cases from routine and study sputum specimens. Detailed results for rifampicin (RIF) and isoniazid
(INH) are provided on the left with combined MDR status on the right




MDR statusa Routine Study
n % of 308 n % of 280
R: Hain R: Hain 86 MDR 232 75.3 55 19.6
R: Hain Discord: Hain S, Pheno R 1
R: Hain & Pheno R: Hain & Pheno 32
R: Hain & Pheno Discord: Hain S, Pheno R 1
R: Pheno R: Pheno 28 3
R: Xpert R: Pheno 1
R: Xpert & Hain R: Hain 46 8
R: Xpert & Hain Discord: Hain S, Pheno R 2
R: Xpert & Pheno R: Pheno 12 35
R: Xpert, Hain, & Pheno R: Hain & Pheno 21 6
R: Xpert, Hain, & Pheno Discord: Hain S, Pheno R 1
Discord: Hain S, Pheno R Discord: Hain S, Pheno R 1
Discord: Xpert R, Pheno R and Sb Discord: Pheno R and Sb 1
Discord: Xpert R, Pheno Sc R: Pheno 1
Discord: Xpert S, Pheno R R: Pheno 1
R: Hain I: Hain 1 RIF R, INH not R 13 4.2 6 2.1
R: Xpert & Hain I: Hain 1
Discord: Xpert R, Hain I I: Hain 1
Discord: Xpert R, Hain S I: Hain 1
R: Xpert & Hain S: Hain 11 2
Discord: Xpert R, Hain S S: Hain 1 1
R: Hain (no results) 7 RIF R, INH no results 62 20.1 63 22.5
R: Xpert (no results) 51 63
R: Xpert & Pheno (no results) 3
Discord: Xpert S, Pheno R (no results) 1
R: Pheno S: Pheno 1 Mono-R to RIF(S to INH) 1 0.3 4 1.4
R: Xpert & Pheno S: Pheno 2
Discord: Xpert R, Pheno Sc S: Pheno 2
S: Xpert & Pheno R: Pheno 2 Mono-R to INH(S to RIF) 2 0.7
S: Hain S: Hain 1 RIF not R, INH not R 2 0.7
Discord: Xpert I, Pheno S S: Pheno 1
I: Xpert (no results) 1 RIF not R, INH no results 13 4.6
S: Xpert (no results) 12
(no results) (no results) 135 No results 135 48.2
TOTAL 308 280 308 100.0 280 100.0
R Resistant; S = Susceptible, I Indeterminate, Discord Discordant results
Hain resistance detected by Hain, Pheno resistance detected phenotypically, Xpert resistance detected by Xpert
aClassified as resistant (R) if resistance reported by any method. If not resistant, noted as “not R”
bPheno R and S: Indirect proportion R, MGIT S
cXpert R, Pheno S by MGIT: could be disputed rpoB mutations
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Discussion
RR-TB was detected in all routinely collected specimens,
but only 75% had documented MDR-TB, illustrating the
need for expanded DST beyond Xpert MTB/RIF in
order to target preventive therapy for HHCs. In many
countries, this may require significant capacity building.
Only about one-third of participants had sputum speci-
mens collected for the study that grew MTB in culture,
thus confirmation of MDR status or expanded DST
post-treatment initiation may not be possible in the ma-
jority of cases. Moreover, this may hinder future com-
parisons of genotype and DST patterns between index
cases and their household contacts for potential scien-
tific investigations.
In our study, we observed considerable heterogeneity
in the testing done on routine and study specimens for
MDR-TB patients across 8 countries, with various com-
binations of molecular and/or phenotypic drug suscepti-
bility tests done in routine care. However, these findings
were useful and informed the design and implementa-
tion of the interventional trial in several aspects.
The first finding illustrates the challenges related to
completing INH DST to confirm MDR status. Routine
testing on all 308 index cases confirmed MTB that was
resistant to rifampicin, but only three-quarters had
evidence of MDR-TB. The majority of those not classi-
fied as MDR-TB were because only RIF resistance was
tested, mainly by Xpert (Table 3), i.e. RR-TB. According
to WHO guidelines, patients with RR-TB should receive
MDR-TB treatment regimens, and MDR-TB and RR-TB
recommendations are typically grouped together [6].
Whether or not INH DST is needed to determine the
ideal treatment regimen for disease has been debated
previously [7]. The WHO now recommends that all
countries move towards universal testing for both isonia-
zid and rifampicin resistance at the start of TB treatment
[6]. From the perspective of selecting appropriate pre-
ventive treatment for close contacts, the drug resistance
pattern of the source case is however an important fac-
tor [8], since HHCs with exposure to MTB susceptible
to INH would benefit from INH-containing regimens
Despite receiving MDR-TB treatment for a median of
59 days, 91% of participants were still able to produce
sputum at enrollment into the feasibility study, of whom
only 53% still had detectable MTB and 20% had MDR-
TB confirmed. Of note, Hain testing was optional for the
study as it was not available in all network laboratories.
After learning that a significant proportion of patients
on treatment for MDR-TB only had evidence of RR-TB,
we therefore decided to make the documentation of
Fig. 1 Venn diagram of routine and study specimens showing proportion with documented MDR-TB, and details of INH and RIF drug
susceptibility testing. Legend: Drug susceptibility testing was performed by molecular and/or phenotypic methods. Of 280 participants providing
on-treatment sputum specimens, MTB was not identified in 133 and so DST could not be performed, MTB was identified but no RIF DST was
performed in 2, and MTB was identified and RIF DST was performed in 145 participants. The area of circles are proportional to the frequencies
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resistance to both RIF and INH in the interventional
trial essential, as the treatment arms include delamanid
and INH.
The second finding concerns the challenges of
completing second line DST. DST results for fluoroqui-
nolones and SLID were limited, so conclusions on pre-
XDR and XDR status should be interpreted with caution.
Only 35% of participants had DST performed for
second-line drugs by the routine TB program. This pro-
portion is likely to become higher as WHO reports that
FLQ and SLID DST in MDR/RR-TB patients is becom-
ing more available, increasing from 49% in 2017 to 59%
in 2018 [1]. Nine percent of participants could not pro-
duce sputum on study. For the 280 participants provid-
ing study specimens, MTB was detected by Hain or
culture in 8 and 30%, leaving only 14% of study speci-
mens with testing sufficient to determine pre-XDR and/
or XDR status. This highlights the additional challenge
of performing further DST on specimens collected after
MDR-TB treatment initiation, where the lower bacillary
load decreases diagnostic yield. All these limitations have
important public health consequences for the appropri-
ate management of XDR-TB.
The third finding regarding the interpretation of
discordant results is complex, especially when testing
is done in specimens obtained at different times and
tested in different laboratories [9]. For example, all
routine specimens were RIF resistant but 17 study
specimens had susceptible or indeterminate RIF re-
sults (Table 3). These could possibly represent muta-
tions missed by the assay (which may be improved by
use of the updated Ultra version [10]), mixed infec-
tions with multiple similar strains, or microevolution
of strains within the host [11] under treatment pres-
sure. There were also three Xpert RIF resistant but
MGIT susceptible results in study specimens (Table
3); these could in fact be false susceptible MGIT RIF
results due to disputed mutations in the rpoB gene
[12]. Discordant results were also observed for INH:
six routine specimens were INH susceptible by Hain
but INH resistant phenotypically; this is a known
limitation of the Hain MTBDRplus assay, which de-
tects only resistance mediated by katG or inhA muta-
tions [13] or 85% of isoniazid resistance detected by
MGIT [14]. Consequently for the intervention trial, a
pragmatic approach using any resistance for RIF and
for INH was adopted for the Index Case MDR-TB
eligibility criteria, as long as considered resistant by
the program at the time of evaluation.
The fourth finding was related to the fact that only
one-third of participants had culture positive sputum
when approached for the study. This would likely impact
the planned interventional study objective of comparing
genotype and DST patterns between index cases and
their household contacts. We shortened the time since
MDR diagnosis from 6months to 3months for the index
case in the interventional trial, which should increase
the rate of culture positivity at study enrollment, imply-
ing that HHCs would have had significant ongoing MTB
exposure at the time of enrolment.
A fifth finding was that among those tested, the
rate of smear positivity was high at 69% in routine
specimens. A third (34%) of study specimens were
still smear positive a median of 59 days after MDR-
TB treatment initiation, highlighting the significant
risk for their exposed household contacts and health-
care workers [15], although this is not necessarily an
indication of viable bacilli. This is also high consider-
ing that effective treatment should render MDR-TB
patients rapidly non-infectious [16]. Almost a third of
routine specimens did not have a smear result docu-
mented, an increasingly common scenario in settings
where Xpert is used universally for rapid detection of
MTB and of rifampicin resistance [17]. Sputum smear
microscopy is often done on a second sputum speci-
men at baseline for treatment monitoring [18]. In the
absence of sputum smear results, Xpert cycle thresh-
old values or ranges could be reported to provide a
quantitative measure of bacillary load reflecting de-
gree of infectiousness at the time of diagnosis [19].
Such data were not collected for this study.
Our study has several limitations. MDR-TB treatment
was provided by the local program and details of patient
adherence or gaps in treatment were not available. Add-
itional testing during treatment may also have been per-
formed by the programs, but we only collected results
from specimens collected at the time of diagnosis. Fi-
nally, some tests could have been done but not recorded
as MDR-TB laboratory reports can be complex to inter-
pret, as multiple tests are done and reported over mul-
tiple days.
Conclusion
The mycobacteriology objectives for this study were to
determine if MTB was detectable and if resistance to
INH and RIF could be confirmed, genotypically and
phenotypically, in adult index cases with drug resistant
TB at time of enrolment. We found that only three
quarters of the index cases had documented MDR-TB
and that for the remainder, this could not be confirmed
on study for most participants. Despite these limitations,
this study provided valuable data and informed improve-
ments to the interventional trial design aimed at evaluat-
ing TB preventive therapy to high-risk HHCs. Our data
also highlight the challenges and importance of careful
and systematic documentation of MDR-TB microbio-
logical results to ensure high-quality data for clinical re-
search and to ensure appropriate TB preventive therapy
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is offered to close contacts. Finally, our study also has
implications for routine care settings in additional to the
research context. Capacity building in TB control pro-
grams is needed to provide the necessary infrastructure
to enable accurate characterization of patients with
MDR-TB, to provide them with optimal therapy, and to
inform the best strategy prevent TB in their household
contacts.
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